Subscribe To

Price Alert Latest News Economic Calendar News

LGVN / Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses

Longeveron obtained Rare Pediatric Designation of Lomecel-B for patients with hypoplastic left heart syndrome. All 10 patients who received Lomecel-B were alive and had not required a transplant between 2 to 3.5 years post-surgery. Read More

Demo Live Account See Partner Details

Content Topics

Vt

Holdings

Co

Ltd

7593

Longeveron

Speculative

Biotech

Disease

Aging

Alzheimer s

Focuses

Stock

LGVN

Posted: Feb 14 2022, 22:01

Author Name: Seeking Alpha

LGVN News

By Market Watch
October 5, 2023

Longeveron stock jumps on Alzheimer's trial results

Longeveron Inc. shares LGVN, +4.58% jumped 16% premarket on Thursday after the clinical-stage biotech company announced positive results from a trial

By Seeking Alpha
August 11, 2023

Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN ) Q2 2023 Earnings Conference Call August 11, 2023 8:00 AM ET Company Participants Mike Moyer - Managing Director, LifeSc

By Seeking Alpha
May 12, 2023

Longeveron Inc. (LGVN) Q1 2023 Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants James Clavijo - Chief Financial Officer W

By InvestorPlace
May 12, 2023

LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates

Longeveron (NASDAQ: LGVN ) just reported results for the first quarter of 2023. Longeveron reported a loss per share of 22 cents.

By InvestorPlace
May 9, 2023

Why Is Longeveron (LGVN) Stock Up 30% Today?

Longeveron (NASDAQ: LGVN ) stock is on the move Tuesday after releasing long-term survival data from its HLHS treatment. According to the company, al

By Market Watch
May 9, 2023

Longeveron stock up 15.5% premarket after positive results in trial of treatment for rare congenital heart defect in infants

Longeveron Inc.'s stock LGVN rocketed 15.5% in premarket trade Tuesday, after the biotech said its Lomecel-B for the treatment of a congenital heart d

By Seeking Alpha
March 10, 2023

Longeveron Inc. (LGVN) Q4 2022 Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN ) Q4 2022 Results Conference Call March 10, 2023 8:30 AM ET Company Participants James Clavijo - CFO Wa'el Hashad - CEO D

By GlobeNewsWire
March 6, 2023

Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023

Live conference call on Friday, March 10 at 8:30 a.m. ET Live conference call on Friday, March 10 at 8:30 a.m. ET

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.